CRISPR Therapeutics (NASDAQ: CRSP) is a healthcare company that makes gene-editing therapies that can transform the lives of patients. While it doesn't have an approved product today, that could change by the end of the year.

The company has come a long way in establishing itself. But just how well has the stock done over the years, and would it have proven to be a good investment if you bought shares at its initial public offering?

Oct. 19, 2016 was officially CRISPR Therapeutics' first day of trading. It opened at a price of $15, so if you invested $30,000 into the business at the time, you'd have been able to buy 2,000 shares. Today, with the stock trading at around $51, your investment would be worth approximately $102,000. That's a return of 240% in a little less than seven years, which averages out to a compounded annual growth rate of 19%.

Continue reading

Source Fool.com